The Safety and Efficacy of Adjunct Carvedilol in Children With Moderate Heart Failure
National Center for Research Resources (NCRR)
We would like to see if using Carvedilol in adjunct with Ace inhibitors will increase
ejection fraction of the heart under echo. All interpretation of data will be sent to Boston
Children's Hospital to be reviewed, which is the primary research center in this study.
There are 5 hospitals participating in this study. The population targeted are children with
moderate heart failure and must be on Ace inhibitors at the time of enrollment. Our outcome
after placing them on Carvedilol is to change their ejection fraction on echo. The patients
will be seen every 1-2 weeks, while we will titrate their medication to a maintenance dose.
Secondary outcome is to increase quality of life, exercise tolerance and decrease their
symptom scores as noted on their questionnaires.
Serving leading biopharmaceutical companies globally:
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Alerts Available With Subscription
Alerts are available for users with active subscriptions.